Carlsbad
(760) 431-2273
Murrieta
(951) 600-9803
Ontario
(909) 947-3600
OPEN 24
HOURS
Clinical Trials & Treatments

Our goal at the CVS Angel Care Cancer Center is to provide the most up-to-date, compassionate care for pets with cancer while supporting the caregivers who bring them to us. We use the very latest therapies available with the objective of enhancing quality of life, every moment of the day. ACCC also constantly strives to practice the latest advances in chemotherapy, surgery and emergency and critical care services. More specifically, we use:

 

Diagnostic Cancer Medicine: Real time, M-mode and color flow ultrasonography (cardiac and abdominal), endoscopy (upper and lower GI, bronchoscopy, rhinoscopy, cystoscopy and vaginoscopy), laparoscopy, bone marrow aspirations and biopsies, diagnostic radiology (x-ray) imaging, including  magnetic resonance imagine (MRI) and PET/CT scans. 


Medical Oncology: Advanced care and diagnostics in endocrinology, gastroenterology, cardiology, nephrology/urology, neurology and hematology, and respiratory medicine, as well as services to combat respiratory and infectious disease. 


Surgical Oncology: The surgical team at ACCC provides special surgical expertise in all aspects of cancer surgery, from minor tumor removal to limb sparing surgery to cancer neurosurgery. 


Radiation Oncology: The team of cancer specialists at ACCC works with physicians who are radiation oncologists to provide veterinary specialists with some of the world's most advanced radiation care for animals.

 

The CVS Angel Care Cancer Center has vertinarians with specialty skills on staff. We have three emergency/critical care specialists specially trained to support the cancer patient in urgent care situations, four internal medicine/medical oncology specialists, and three cancer surgery specialists. ACCC facilities feature full-service in-house clinical laboratories, on-site pharmacies, surgical suites, and separate ICU and temperature-controlled wards with soft, comfortable bedding. The facilities boast state-of-the-art diagnostic equipment, including color-flow Doppler ultrasound, laparoscopy, video endoscopy, arthroscopy and the West Coast's only functioning hyperbaric oxygen chamber for animals. ACCC features special visitation rooms so animals can spend quality private time with their human families in a quiet and relaxing environment.

 

Current Clinical Trials In Progress:


Study Title: Voyager, a non-invasive anti-cancer medical device. Voyager emits specific low level radio frequency energy that blocks cancer cells from dividing by blocking the dis-assembly of microtubule, leading to aberration, multi-nucleation and interruption of mitotic spindle activity during cell division, at metaphase
Eligibility: All dogs in good health with confirmed maligancies
Hypothesis: We hypothesize that Voyager is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)


Study Title: Genelux Phase I/II Clinical Trial to Evaluate Viral Anticancer Therapy for Canine Malignancies

Eligibility: All dogs in good health with confirmed  Malignancies
Hypothesis: We hypothesize that the Genelux construct  is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: MoAb Phase I/II Clinical Trial to Evaluate a Immunotherapy Anticancer Therapy for Canine B cell Lymphoma
Eligibility: All dogs in good health with confirmed 
Hypothesis: We hypothesize that the MoAb is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: MoAb Phase I/II Clinical Trial to Evaluate a Immunotherapy Anticancer Therapy for Canine T cell Lymphoma
Eligibility: All dogs in good health with confirmed 
Hypothesis: We hypothesize that the MoAb is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: MoAb Phase I/II Clinical Trial to Evaluate CHOP plus immunotherapy Anticancer Therapy for Canine B cell Lymphoma
Eligibility: All dogs in good health with confirmed 
Hypothesis: We hypothesize that the MoAb is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)

Study Title: Voyager, a non-invasive anti-cancer medical device. Voyager emits specific low level radio frequency energy that blocks cancer cells from dividing by blocking the dis-assembly of microtubule, leading to aberration, multi-nucleation and interruption of mitotic spindle activity during cell division, at metaphase
Eligibility: All dogs in good health with confirmed maligancies
Hypothesis: We hypothesize that Voyager is safe and effective for the treatment of cancer in animals
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)

 
Study Title:  An open label, prospective, multicenter, randomized, 2-parallel groups, phase 2 study to compare efficacy and safety of masitinib (single agent) to human tyrosinase (huTyr) DNA vaccine (single agent), with a randomization 1:1, in the treatment of dogs with malignant melanoma expressing mutated c-kit post surgery (+/-radiotherapy) 
Eligibility: All dogs in good health with confirmed 
Hypothesis: We hypothesize that mastinib alone will be equal to the melanoma vaccine and that mastinib and the melanoma vaccine is superior to the vaccine alone.
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)

Study Title: An open label, prospective, multicenter, randomised, 3-parallel groups, phase 2 study to compare efficacy and safety of masitinib (single agent),masitinib in combination with doxorubicin and doxorubicin (single agent),with a randomization 1:1:1, in treatment of dogs with splenic hemangiosarcoma post splenectomy 
Eligibility: All dogs in good health with confirmed 
Hypothesis: We hypothesize that masitinib (single agent) is not as effective as ,masitinib in combination with doxorubicin but superior to doxorubicin for the treatment of dogs with splenic hemangiosarcoma post splenectomy 
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: An open label, prospective, multicenter, randomized, 2-parallel groups, phase 2 study to compare efficacy and safety of masitinib in combination with doxorubicin to Human tyrosinase (huTyr) DNA vaccine (single agent), with a randomization 1:1, in the treatment dogs with malignant melanoma post surgery +/- radiotherapy 
Eligibility: All dogs in good health with confirmed  malignant melanoma
Hypothesis: We hypothesize that masitinib in combination with doxorubicin  is superior to human tyrosinase (huTyr) DNA vaccine (single agent) for the treatment of dogs with malignant melanoma post surgery +/- radiotherapy 
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)

Study Title: An open label, prospective, multicenter, randomized, 3-parallel groups, phase 2 study to compare efficacy and safety of AB1010 (single agent), AB1010 in combination with doxorubicin and doxorubicin (single agent), with a randomization 1:1:1, in the treatment of dogs with advanced or not T cell lymphoma
Eligibility: All dogs in good health with confirmed  T cell lymphoma
Hypothesis: We hypothesize that AB1010 will have an anticancer effect on her own and that AB1010 will enhance the efficacy of doxorubicin for the treatment of T cell lymphoma
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: Poladium Lipoic Acid Study: Randomized, placebo controlled, double blind prospective study (3:1) for the treatment of dogs and cats with cancer
Eligibility: All dogs in good health with confirmed malignancies
Hypothesis: We hypothesize that PolyMVA will enhance and improve quality of life
Questions? Contact Drs. Ogilvie or Proulx or oncology nurses Lee or Maggie (760-431-2273/951-600-9803)

Study Title: Chemotherapy/Tyrosine Kinase Receptor antagonist Kinavet study
Financial Obligations: Partial Financial Support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: Therapeutic Apheresis for Canine Cancer
Eligibility: All medium to large sized dogs in good health with histologically confirmed measurable cancer, especially malignant melanoma
Hypothesis: We hypothesize that therapeutic apheresis will safely and effectively remove an inhibitor of the immune system and subsequently cure or control metastatic and non metastatic measurable cancer, especially malignant melanoma in the dog.
Financial Obligations: Partial financial support
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)
 
Study Title: Palladium/lipoic Acid Oxidative Stress Study
Eligibility: All dogs in good health with confirmed malignancies that are in remission
Hypothesis: We hypothesize that the palladium/lipoic acid complex, an oral medication designed to enhance quality of life and to have some anticancer effects, will safely and effectively benefit dogs with  a wide variety of cancers.
Financial Obligations: The palladium/lipoic acid complex and the simple urine tests are free.
Questions? Contact (760-431-2273/951-600-9803/909-431-3600)




PREV STEPNEXT STEP


RELATED ARTICLES
CVS Wins 2008 Hospital Design Merit Award
Jan 16, 2012
An open facility is more than a building design; it's a way of life at California Veterinary Specialists in Carlsbad, California. The doctors at this practice share space and cases in a convenient, free-flowing facility. There's no such thing as my caseor your caseat California Veterinary Specialists in Carlsbad, Calif. Every doctor shares cases, information, and expertise to ...
Diagnosis
Staging, Grading: Imagine defeating an enemy you did not know. What is the threat? What are the tools to defeat this enemy? This is exactly what your veterinarian is thinking when he or she considers staging or grading the cancer: Understanding where the cancer is in the body, the name of the cancer and the degree of aggressiveness. By understanding the enemy, we can defeat it. • Each tumor is different and unique. Each one must first be given a name; this is only possible with a biopsy or cytology (a test that helps determine the type ..
Health & Wellness Recommendations by Age
Jan 01, 2012
Components of Health and Wellness Programs by Age (<1 Year of Age, 1-7 Years of Age, >7 Years of Age). For animals <1 Year of Age: -Preadoption counseling to select breeds and lines with a reduced risk of cancer and to meet the needs of the adopting family. -Behavioral counseling and suggestions regarding obedience classes. -A complete History. -A complete physical examination. Read more!
What Is Cancer and What Causes It
The word cancer is as dark and empty as the disease it defines. A cancer diagnosis often brings feelings of overwhelming fear, a loss of control, and most devastating of all, a loss of hope. This can occur regardless of whether the patient is a friend, family member or a precious pet. When we face the diagnosis of cancer in a beloved pet it is even more difficult, for we must make important and life changing decisions for our animal friends that rely totally on our own judgments for their well-being. These animals not only share our homes, our
Where To Begin
Cancer is the number one natural cause of death in geriatric cats and dogs, and it accounts for nearly 50 percent of pet deaths each year. Although cancer is the leading cause of death in geriatric patients, it's also the most treatable disease when compared with life-limiting diseases like congestive heart failure, renal failure and diabetes. An educated and dedicated veterinary health care team is essential to compassionately care for cancer patients. Compassionate care of your pet can only be accomplished with a team, and you are the cente